Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Erhaltungstherapien beim Ovarialkarzinom: Zusatznutzen zielgerichteter Therapien

Maintenance therapy in ovarian cancer: added value of targeted therapies

  • 193 Accesses

Zusammenfassung

Trotz erfolgreicher Primärtherapie erleiden bis zu 70 % der Patientinnen mit Ovarialkarzinom ein Rezidiv. Nachdem eine Erhaltungstherapie mit konventioneller Chemotherapie sich als wenig effektiv bei starker Toxizität erwiesen hat, scheint der Einsatz zielgerichteter biologischer Therapien erfolgreicher. Sowohl in der Primärtherapie als auch beim Rezidiv gibt es multiple Substanzen, die in klinischen Studien zum Einsatz kommen; am weitesten fortgeschritten ist die Therapie mit Bevacizumab, das bereits für mehrere Indikationen zugelassen ist. Allerdings fehlen bisher Marker als Prädiktoren für den Erfolg einer Therapie.

Abstract

Despite recent achievements in the therapy of primary ovarian cancer (OC), a significant number of patients still relapse. Several clinical trials have shown that maintenance therapy with conventional chemotherapeutic drugs is less effective while leading to more morbidity due to toxicity; therefore, current research is focusing on maintenance therapy with targeted agents. Multiple biologic drugs are being applied in clinical trials for both primary and relapsed OC, with bevacizumab yielding the most clinical data to date. However, biological markers predictive of successful therapy are largely missing.

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.

    Bois A du, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115(6):1234–1244. doi:10.1002/cncr.24149

  2. 2.

    Markman M, Liu PY, Wilczynski S et al (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21(13):2460–2465

  3. 3.

    Pecorelli S, Favalli G, Gadducci A et al (2009) Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol 27(28):4642–4648. doi:10.1200/JCO.2009.21.9691

  4. 4.

    Mannel RS, Brady MF, Kohn EC et al (2011) A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 122(1):89–94. doi:10.1016/j.ygyno.2011.03.013

  5. 5.

    Mei L, Chen H, Wei DM et al (2013) Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst Rev 6:CD007414. doi:10.1002/14651858.CD007414.pub3

  6. 6.

    Sabbatini P, Harter P, Scambia G et al (2013) Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO – the MIMOSA study. J Clin Oncol 31(12):1554–1561. doi:10.1200/JCO.2012.46.4057

  7. 7.

    Gregorio N de,·Ebner F, Janni W, Wöckel A (2013) Biologicals beim Ovarialkarzinom. Stand der Entwicklung. Gynakologe 46:666–671

  8. 8.

    Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484–2496. doi:10.1056/NEJMoa1103799

  9. 9.

    Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473–2483. doi:10.1056/NEJMoa1104390

  10. 10.

    Kristensen G, Harter P, Trédan O et al (2014) Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC). J Clin Oncol 32:5s (suppl; abstr 5556^)

  11. 11.

    Du Bois A, Floquet A, Weon Kim J et al (2013) Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international Intergroup trial (AGO-OVAR16). J Clin Oncol (suppl; abstr LBA5503)

  12. 12.

    Vergote IB, Jimeno A, Joly F et al (2014) Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol 32(4):320–326. doi:10.1200/JCO.2013.50.5669

  13. 13.

    Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32(13):1302–1308. doi:10.1200/JCO.2013.51.4489

  14. 14.

    Stockler MR, Hilpert F, Friedlander M et al (2014) Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 32(13):1309–1316. doi:10.1200/JCO.2013.51.4240

  15. 15.

    Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30(17):2039–2045. doi:10.1200/JCO.2012.42.0505

  16. 16.

    Rigakos G, Razis E (2012) BRCAness: finding the Achilles heel in ovarian cancer. Oncologist 17(7):956–962. doi:10.1634/theoncologist.2012-0028

  17. 17.

    Alsop K, Fereday S, Meldrum C et al (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21):2654–2663. doi:10.1200/JCO.2011.39.8545

  18. 18.

    Ledermann J, Harter P, Gourley C et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366(15):1382–1392. doi:10.1056/NEJMoa1105535

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. N. de Gregorio, P. Widschwendter, W. Janni und F. Ebner geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Correspondence to Dr. N. de Gregorio.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

de Gregorio, N., Widschwendter, P., Janni, W. et al. Erhaltungstherapien beim Ovarialkarzinom: Zusatznutzen zielgerichteter Therapien. Gynäkologe 47, 966–970 (2014). https://doi.org/10.1007/s00129-014-3490-1

Download citation

Schlüsselwörter

  • Maligne Tumoren
  • Biologika
  • Chemotherapie
  • Bevacizumab
  • Rezidiverkrankung

Keywords

  • Malignant tumors
  • Biologics
  • Chemotherapy
  • Bevacizumab
  • Recurrent disease